A crucial correction in the landmark GLISTEN trial for liver disease
A correction has been issued for the pivotal GLISTEN phase 3 trial published in The Lancet Gastroenterology & Hepatology. The trial investigated the efficacy of linerixibat, a novel ileal bile acid transporter inhibitor, for treating the debilitating cholestatic pruritus associated with primary biliary cholangitis. The correction clarifies a data presentation error in Figure 3, specifying that the first row of participant numbers under “Treatment in part A” corresponds to the placebo group, while the second row represents the linerixibat group. This update ensures the accurate interpretation of patient retention and treatment response data over the study’s timepoints, which is critical for assessing the drug’s long-term profile and safety in managing this chronic liver condition.
Study Significance: For hepatologists and gastroenterologists managing primary biliary cholangitis, precise data from high-impact trials like GLISTEN directly informs clinical decision-making and patient counseling regarding new therapeutic options for refractory pruritus. This correction underscores the importance of data integrity in translational medicine, as even minor labeling errors can affect the interpretation of a drug’s tolerability and efficacy curve. It reinforces the need for meticulous review of published figures when integrating new agents like bile acid modulators into treatment algorithms for cholestatic liver diseases.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
